
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): August 17, 2010

Arrowhead Research Corporation

(Exact name of registrant as specified in its charter)

0-21898
**(Commission
File Number)**

Delaware
**(State or other jurisdiction
of incorporation)**

46-0408024
**(IRS Employer
Identification No.)**

201 South Lake Avenue, Suite 703, Pasadena, CA 91101
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (626) 304-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers

(b) Resignation of Directors

On August 17, 2010, LeRoy T. Rahn resigned from his position on the Board of Directors of Arrowhead Research Corporation (the “Company”). Mr. Rahn’s resignation was not due to any disagreement with the Company or the Board relating to the Company’s operations, policies or practices.

(d) Appointment of Directors

On August 18, 2010, Dr. Mauro Ferrari was elected to the Company’s Board of Directors to fill the vacancy caused by the resignation of Mr. Rahn. Dr. Ferrari has been a member of the Company’s Scientific Advisory Board, and is a member of the Board of Directors of Leonardo Biosystems, Inc., a company in which the Company owns a minority interest holding of approximately 5%. It is expected that Dr. Ferrari will serve on the Board’s Audit, Nominating and Compensation Committees. In connection with his appointment to the Board, Dr. Ferrari was granted an option to purchase up to 200,000 shares of Company common stock, which option vests over a four-year period in lieu of the standard cash compensation normally paid to independent directors.

